In another abysmal day for large pharma companies’ off-patent drugs, generics makers have once again offered hefty discounts to win large tender offers in China, elbo...

If CureVac's patent infringement lawsuit against BioNTech is successful, the company could be lined up to receive serious royalties from its fellow German mRNA pionee...

Struggling biotech Athenex unloaded all of its equity interests in its Chinese subsidiaries that produce APIs as part of a $19 million deal with TiHe Capital of Beiji...

ROCKVILLE, MARYLAND—Regenxbio CEO Ken Mills motions toward a window pointing out a building to the north, barely visible beneath a small grove of trees. “That’s w...

Blaming the “supply chain” has almost become a punch line—the go-to excuse for explaining any negative performance. But these days it’s among a legitimate set of ...

Pfizer has turned itself into a household name amid the pandemic, but it's routinely looking at ways to improve on its operations. In one approach, the company is exp...

Roche’s Lunsumio could soon become the first bispecific to join the U.S. treatment armamentarium for non-Hodgkin lymphoma. Wednesday, Roche said the FDA has put i...

After nearly seven months and two prior recalls, Viatris continues to be vexed by labeling issues on its biosimilar to Sanofi’s diabetes blockbuster Lantus. ...

Who's tops in ESG in the pharma industry? If you ask patient groups, it's ViiV, Roche and Pfizer, That's according to a new report from PatientView, which tapped ...

Developing an antibody treatment that is effective against the omicron variant of COVID-19 has paying off for Eli Lilly. But the company may soon lose its primary cus...